Metazydyna (Trimetazidine Dihydrochloride)

Trimetazidine inhibits mitochondrial fatty‑acid β‑oxidation, shifting the heart’s energy production toward glucose oxidation. This metabolic change requires less oxygen, preserving ATP levels during ischemia and reducing chest pain or tissue damage associated with reduced blood flow.

The specific dose of Metazydyna is determined by the prescribing physician based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for trimetazidine in pregnancy and lactation are limited. It is generally recommended to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their doctor.

To request Metazydyna, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Unlike beta‑blockers or calcium‑channel blockers that primarily affect heart rate or vascular tone, Metazydyna acts on cellular metabolism, improving energy efficiency without significantly altering hemodynamics. This makes it a useful adjunct or alternative for patients who cannot tolerate traditional anti‑anginal agents.

Metazydyna should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Metazydyna is taken orally, usually with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse reactions, although rare, include severe allergic responses, liver enzyme elevations, thrombocytopenia, significant hypotension, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms such as rash, swelling, jaundice, unexplained bruising, or fainting.

Metazydyna is contraindicated in patients with known hypersensitivity to trimetazidine or any of its excipients. Caution is also advised for individuals with severe renal or hepatic impairment, uncontrolled hypotension, or those taking dopamine antagonists that may increase the risk of extrapyramidal side effects.